医科学専攻

  • Master's Courses 
    修士課程
  • Doctoral Courses 
    博士課程

Gynecology婦人科学

  • 婦人科腫瘍学
  • 生殖内分泌学
  • 女性医学
  • 女性漢方

STAFF

Professor

  • Saito, MasatoshiProfessor. 齋藤 昌利 教授 (兼任)

Other Faculty / Staff

  • Shimada, Muneaki
    Assoc. Prof. 島田 宗昭 准教授
  • Shigeta, Shogo
    Assistant Prof. 重田 昌吾 助教

CONTACT

TEL:+81-22-717-7251
E-MAIL:ob-gy*med.tohoku.ac.jp
(「*」を「@」に変換してください)

OUTLINE

Our department provides professional medical care for the patients with a wide range of gynecologic diseases such as malignant and benign tumors, endocrine disorders, and other health care problems. As for gynecologic tumors, more than two-hundreds of the patients with gynecologic cancer are treated every year. We proactively offer minimally invasive surgeries or fertility-sparing surgeries for the eligible patients. In the field of reproductive endocrinology and infertility, we provide comprehensive treatment including advanced assisted reproductive technology, laparoscopic or hysteroscopic surgeries and falloposcopic tuboplasty. We also offer interdisciplinary approaches for the patients with adolescent menstrual disorders, disorders of sex development, gender dysphoria, etc.
In basic research, we have been reported plenty of studies about candidate therapeutic targets for gynecologic cancer refractory to the standard treatment. Our laboratory also has been engaged in infertility research focusing on the function of cytoplasm and mitochondria in embryo. Our current research interest is also in advancing translational research. As an example, we have reported a feasibility study on clinical application of chip-sensing embryo respiratory measurement system in collaboration with industry. In addition, we are focusing on multi-omics analysis to find novel biomarkers for gynecologic malignancy as a collaboration project with Tohoku Medical Megabank.

婦人科悪性腫瘍、良性腫瘍、婦人科内分泌疾患をはじめ、希少疾患も含め女性のヘルスケア全般にわたる幅広い疾患の診断や治療を行っています。婦人科腫瘍に関しては年間200例以上の新規がん症例を取り扱っており、ロボット支援手術などによる低侵襲手術や妊孕性温存を考慮したがん根治手術を適格症例中心に積極的に取り入れています。生殖内分泌の領域では高度生殖医療技術に加え、鏡視下手術や卵管鏡による卵管形成などを応用し包括的な不妊治療を展開しています。また、思春期月経異常、性分化疾患、性同一障害に対しては他科と連携しながら患者さん個々の状態に応じた治療を提供しています。新規治療法の検証のため臨床試験、医師主導試験にも精力的に取り組んでいます。
基礎研究ではこれまで難治性婦人科癌に対する新規治療標的の同定、細胞質やミトコンドリアの機能に着目した受精卵の研究をおこなってきました。近年では胚呼吸に着目した受精卵の評価方法についての産学連携研究、また東北大学メディカル・メガバンクとの連携によるマルチオミックス解析を通した婦人科癌新規バイオマーカー探索など基礎と臨床をつなぐトランスレーショナルリサーチにも注力しています。

  • Metabolomic analysis in ovarian cancer (cited from reference No.2)
    卵巣癌メタボローム解析(文献2より)

  • Research on cytoplasm of embryo (cited from reference No. 1)
    受精卵細胞質に関する研究(文献1より)

  • Members in the department of gynecology
    婦人科学分野一同

ARTICLE

Tokunaga H, et al. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). PLoS One. 2021;16(1):e0236907.
URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236907

Hishinuma E, et al. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer. Toxins (Basel). 2021;13(7).
URL:https://www.mdpi.com/2072-6651/13/7/461

Fujimine-Sato A, et al. Exploration of the Cytoplasmic Function of Abnormally Fertilized Embryos via Novel Pronuclear-Stage Cytoplasmic Transfer. Int J Mol Sci. 2021;22(16).
URL:https://www.mdpi.com/1422-0067/22/16/8765

Kudo K, et al. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer. FEBS Lett. 2020;594(9):1379-88.
URL:https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.13736

Kurosawa H, et al. Development of a new clinically applicable device for embryo evaluation which measures embryo oxygen consumption. Hum Reprod. 2016;31(10):2321-30.
URL:https://academic.oup.com/humrep/article/31/10/2321/2389059

一覧へ戻る
ページトップへ戻る